U.S. Silica Company v. Amberger Kaolinwerke Eduard Kick GmbH & Co. KG

District Court, E.D. Texas·Decided March 29, 2023·No. 2:20-cv-00298·Unknown

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF TEXAS MARSHALL DIVISION

U.S. SILICA COMPANY, § § Plaintiff, § § v. § CIVIL ACTION NO. 2:20-CV-00298-JRG § AMBERGER KAOLINWERKE EDUARD § KICK GMBH & CO. KG, § § Defendant. §

MEMORANDUM OPINION AND ORDER GRANTING INJUNCTIVE RELIEF Before the Court is U.S. Silica Company’s (“U.S. Silica”) Motion for Permanent Injunction, or Alternatively, For an Ongoing Royalty on Future Sales (the “Motion”). (Dkt. No. 282). Having considered the Motion, the related briefing, and the applicable law, the Court is of the opinion that the Motion should be GRANTED-AS-MODIFIED. I. BACKGROUND 1. The Claimed Invention and U.S. Silica’s Business In 2017, U.S. Silica purchased National Coatings Corporation’s (“National Coatings”) intellectual property. (Dkt. No. 260 at 178:2–6). National Coatings’ patent portfolio included the Asserted Patents.1 (Id. at 178:2–6; 198:20–199:11). Prior to the sale, Amberger Kaolinwerke Eduard Kick Gmbh & Co. KG (“AKW”) manufactured calcined kaolin-based granules for National Coatings’ roof coating. (Dkt. No. 262 at 162:23–25). National Coatings marketed the product manufactured by AKW as “White Armor.” (Id. at 163:1–2). Initially after U.S. Silica purchased National Coatings, U.S. Silica relied on AKW to produce the White Armor granules. (Dkt. No. 261 at 244:13–245:7). However, in 2018, U.S. Silica decided to open an operation in order to manufacture its own granules. (Dkt. No. 262 at 64:6–10). To achieve this, U.S. Silica purchased a plant in Georgia. (Dkt. No. 261 at 245:19–246:12). U.S. Silica advised AKW of its purchase of the plant and its intent to shift production of White Armor internally in 2020. (Id. at 245:19–246:12). During those discussions, U.S. Silica offered to give AKW a license to sell White Armor to the European market and possibly to the rest of the world. (Id. at 247:5–10). AKW

rejected U.S. Silica’s proposal. (Id. at 249:7–9). 2. AKW’s Business Following U.S. Silica’s decision to manufacture White Armor internally, AKW unveiled a new product called “AKCool.” (Id. at 270:5–20). This product is a roofing granule intended to be applied to asphalt/bitumen sheets. (Id. at 97:12–98:16). According to AKW’s marketing materials, AKCool particles are identical to the White Armor particles in size, reflectivity, and coating. (Dkt. No. 301 at 4). Since 2019, AKW has sold 124 metric tons of AKCool in the United States. (Dkt. No. 262 at 10:10–16). 3. Competition between AKW and U.S. Silica

Following the rollout of the AKCool product, AKW sought to directly compete with U.S. Silica. (Dkt. No. 261 at 249:17–250:13). It aggressively marketed the AKCool product during at least one roofing convention in the United States. (Id. at 250:14–252:1). On at least two occasions, AKW sold AKCool to United States roofing manufacturers. (Dkt. No. 262 at 10:17–11:5). U.S. Silica alleged that the sale of AKCool resulted in AKW’s customers’ direct and indirect infringement of the Asserted Patents. (Dkt. No. 1). At trial, U.S. Silica demonstrated that Johns Manville and U.S. Ply, who had been U.S. Silica customers, elected to purchase AKCool in lieu of the White Armor product. (Dkt. No. 262 at 10:17–11:5). As a result of AKW’s competition, U.S. Silica lost approximately $75,000 in profits to AKW from September 2019 to August 31, 2020. (Id. at 28:16–25; Dkt. No. 257 at 7). 4. Procedural Posture Following a four-day trial, the jury returned a unanimous verdict in U.S. Silica’s favor on all counts. (Dkt. No. 257). Specifically, the verdict found, among other things, that AKW willfully infringed the Asserted Patents, that the Asserted Claims2 were not invalid, and awarded U.S. Silica $75,229.00. (Id.).

U.S. Silica seeks a permanent injunction enjoining AKW “as well as its subsidiaries, successors, assigns, officers, directors, agents, servants, employees, attorneys, and persons in active concert or participation with them (including any affiliated entities)” from “infringing, directly or indirectly, or inducing infringement of any of the Asserted Claims by making, using, selling, offering, or assisting others in offering the AKCool granule adjudged to have infringed the Asserted Patents or any other cool roofing granule not more than colorably different from the AKCool granule” and from “making, using, selling, offering to sell or inducing any others to make, use, or offer to sell any cool roofing granules like those adjudicated in this case or not more colorably different therefrom.” (Dkt. No. 282-1). U.S. Silica further requests that AKW be

enjoined from “advertis[ing] or otherwise communicat[ing] that they are permitted to engage in any of the conduct described above.” (Id.). II. LEGAL STANDARD The Patent Act provides that in cases of patent infringement, a court “may grant injunctions in accordance with the principles of equity to prevent the violation of any right secured by patent, on such terms as the court deems reasonable.” 35 U.S.C. § 283. To obtain injunctive relief, U.S. Silica must show: “(1) that it has suffered an irreparable injury; (2) that remedies available at law, such as monetary damages, are inadequate to compensate for that injury; (3) that, considering the

2 Claim 9 of the ’303 Patent, Claim 9 of the ’407 Patent, and Claims 1–3 of the ’245 Patent (the “Asserted Claims”). balance of hardships between the plaintiff and defendant, a remedy in equity is warranted; and (4) that the public interest would not be disserved by a permanent injunction.” eBay v. MercExchange, L.L.C., 547 U.S. 388, 391 (2006). Under some circumstances, however, awarding an ongoing royalty for patent infringement in lieu of an injunction may be appropriate. Paice LLC v. Toyota Motor Corp., 504 F.3d 1293, 1314 (Fed. Cir. 2007).

The Court now turns to the eBay factors to determine whether, on balance, the principles of equity support the issuance of a permanent injunction in this case. III. DISCUSSION 1. Irreparable Injury “The essential attribute of a patent grant is that it provides a right to exclude competitors from infringing the patent.” Acumed LLC v. Stryker Corp., 551 F.3d 1323, 1328 (Fed. Cir. 2008) (citing 35 U.S.C. § 154(a)(1)). “In view of that right, infringement may cause a patentee irreparable harm not remediable by a reasonable royalty.” Id. “Price erosion, loss of goodwill, damage to reputation, and loss of business opportunities are all valid grounds for finding irreparable harm.”

Celsis In Vitro, Inc. v. CellzDirect, Inc., 664 F.3d 922, 930 (Fed. Cir. 2012) (citations omitted). Injunctive relief, however, is prospective, requiring “a showing of irreparable injury, a requirement that cannot be met where there is no showing of any real or immediate threat that the plaintiff will be wronged again.” City of Los Angeles v. Lyons, 461 U.S. 95, 96 (1983); Innogenetics, N.V. v. Abbott Labs., 512 F.3d 1363, 1380 (Fed. Cir. 2008) (injunctive relief was improper when the jury’s damages award included both a market entry fee and an on-going royalty, by which the patentee had been fully compensated). Here, the parties substantially disagree about the prospects of future infringement by AKW. AKW concedes, and U.S. Silica acknowledges, that in response to U.S.

Free access — add to your briefcase to read the full text and ask questions with AI

U.S. Silica Company v. Amberger Kaolinwerke Eduard Kick GmbH & Co. KG, (E.D. Tex. 2023).

U.S. Silica Company v. Amberger Kaolinwerke Eduard Kick GmbH & Co. KG (U.S. Silica Company v. Amberger Kaolinwerke Eduard Kick GmbH & Co. KG) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

City of Los Angeles v. Lyons
461 U.S. 95 (Supreme Court, 1983)
ACUMED LLC v. Stryker Corp.
551 F.3d 1323 (Federal Circuit, 2008)
Innogenetics, N v. v. Abbott Laboratories
512 F.3d 1363 (Federal Circuit, 2008)
Paice LLC v. Toyota Motor Corp.
504 F.3d 1293 (Federal Circuit, 2007)
Sanofi-Synthelabo v. Apotex, Inc.
470 F.3d 1368 (Federal Circuit, 2006)
Robert Bosch LLC v. Pylon Manufacturing Corp.
659 F.3d 1142 (Federal Circuit, 2011)
Celsis in Vitro, Inc. v. CellzDirect, Inc.
664 F.3d 922 (Federal Circuit, 2012)
Zoltek Corp. v. United States
672 F.3d 1309 (Federal Circuit, 2012)
Apple, Inc. v. Samsung Electronics Co., Ltd.
678 F.3d 1314 (Federal Circuit, 2012)